Investigating the Efficacy of Probiotics in Enhancing Gastrointestinal and Immunological Health

ConditionIntestinal and Lmmune Function Lmproved

Trial statusNot yet recruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18-45

SponsorWecare Probiotics Co., Ltd.

About this trial

Evaluate the effectiveness and safety of Ligilactobacillus salivarius LS97 as a food supplement compared to a placebo in improving intestinal and immune functions in healthy adults.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Willing to undergo 3 follow-up visits during the intervention period

Be willing to provide blood, urine and stool samples 2 times during the intervention period

Good eyesight, can read and write, can wear glasses

Have good hearing and be able to hear and understand all instructions during the intervention

Disqualifiers

Digestive diseases, mainly gastrointestinal diseases (celiac disease, ulcerative colitis, Crohn's disease)

Have a serious neurological condition (epilepsy, stroke, severe head trauma, meningitis in the last 10 years, brain surgery, brain tumor prolonged coma - not including general anaesthesia)

Have received/are receiving treatment for the following mental disorders: alcohol/drug/substance abuse dependence, schizophrenia psychosis, bipolar disorder

Take medication for depression or low mood

Trial design

Design model

Parallel

Treatments tested in this trial

Probiotic
Dietary supplement
The trial period of this study lasts for 2 months (8 weeks), during which each participant will have 3 visits (at month 0, month 1, and month 2).
Placebo
Dietary supplement
The trial period of this study lasts for 2 months (8 weeks), during which each participant will have 3 visits (at month 0, month 1, and month 2).

Treatment groups

40 Participants

are divided into 2 treatment groups

Group A: Probiotic groupActive comparator 1 intervention

Group B: Placebo groupPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

Change in the composition of fecal microbiota before and after intervention.

Analyzed by 16S rRNA sequencing.

Time frame

Week 0 and Week 8

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Wecare Probiotics Co., Ltd.

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: